# Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants

> **NCT05307978** · PHASE1 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ALXN1910
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05307978
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-12
- **Primary completion:** 2023-02-07
- **Final completion:** 2023-02-07
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05307978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05307978, "Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05307978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*